AVI 4065

Drug Profile

AVI 4065

Alternative Names: AVI-4065

Latest Information Update: 13 Aug 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AVI BioPharma
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 13 Aug 2007 Discontinued - Phase-I/II for Hepatitis C treatment in USA (SC)
  • 20 Nov 2006 Clinical data have been added to the pharmacokinetics section
  • 05 Oct 2006 Interim results from a phase I/II clinical trial in patients with Hepatitis C Virus Infection have been added to the adverse events, pharmacokinetics and Viral Infections therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top